Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (Ticagrelor, Prasugrel)?

Current Cardiology Reports

Volumn 14, Issue 4, 2012, Pages 486-492

  Varenhorst, Christoph ^a,b   James, Stefan ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

Acute coronary syndrome; Antiplatelets; Clopidogrel; Coronary artery disease; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CONSERVATIVE TREATMENT; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; PATIENT IDENTIFICATION; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; RISK REDUCTION; STENT THROMBOSIS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; HEMORRHAGE; HUMANS; MYOCARDIAL ISCHEMIA; PATIENT SELECTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES;

EID: 84865605314     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0273-y     Document Type: Article

References (27)

1. Hamm CW, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC. Eur Heart J. 2011;32(23):2999-3054.
2. Task Force on Myocardial Revascularization of the European Society of, C., et al., Guidelines on myocardial revascularization. Eur Heart J, 2010. 31(20): P. 2501-55.
3. Yusuf S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. (Pubitemid 32758501)
4. Sabatine MS, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179-89. (Pubitemid 40397259)
5. Steinhubl SR, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288(19):2411-20. (Pubitemid 35340537)
6. Trenk D, et al. Cytochrome P450 2 C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925-34. (Pubitemid 351636443)
7. Taubert D, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80(5):486-501. (Pubitemid 44767878)
8. Neubauer H, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur Heart J. 2003;24(19):1744-9. (Pubitemid 37236863)
9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-39.
10. Bhatt DL, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354 (16):1706-17.
11. •• CURRENT-OASIS 7 Investigators, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930-42. The paper presents the main results of the dose selection study of clopidogrel showing that increasing the dose does not improve outcome overall but increases bleeding risk.
12. Mehta SR, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet. 2010;376(9748):1233-43.
13. •• Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15. This is the main paper of the TRITON trial that provided evidence for the superiority of prasugrel over clopidogrel for reduction of ischemic events but with an increase in overall major bleeding events. The paper includes the results of major subgroups. (Pubitemid 350106708)
14. Wiviott SD, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation. 2005;111(25):3366-73. (Pubitemid 40931949)
15. Wiviott SD, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923-32. (Pubitemid 350291199)
16. • Montalescot G, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for STelevation myocardial infarction (TRITON-TIMI 38): Doubleblind, randomised controlled trial. Lancet. 2009;373(9665):723-31. The ST-elevation subgroup of patients in the TRITON trial that provides evidence that prasugrel was superior to clopidogrel for reduction of ischemic events without increasing bleeding events.
17. Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57. This is the main paper of the PLATO trial that provided evidence for the superiority of ticagrelor over clopidogrel for reduction of ischemic events and mortality without any significant increase in overall major bleeding events but with an increase of spontaneous bleeding events. The paper includes the results of major subgroups.
18. Cannon CP, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-STsegment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50(19):1844-51. (Pubitemid 350007959)
19. Steg PG, et al. Ticagrelor versus clopidogrel in patients with STelevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010;122(21):2131-41.
20. • James SK, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: Substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527. The noninvasive subgroup of the PLATO trial that showed a marked benefit of ticagrelor over clopidogrel in patients not initially planned for invasive management.
21. Chin CT, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST- segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J. 2010;160(1):16 e1-22 e1.
22. • Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57(6):672-84. The subgroup of patients in the PLATO trial that underwent CABG with a marked benefit of ticagrelor over clopidogrel and a substantial reduction in mortality.
23. Varenhorst C, A.U., Scirica B et al. Cardiac events, infections and bleeds contribute to higher vascular and non-vascular mortality with clopidogrel compared to ticagrelor in patients undergoing coronary artery bypass grafting. in ESC Congress 2011. 2011. Paris.
24. Smith PK, D.G., Goodnough LT, Mortality benefit with prasugrel in TRITON-TIMI 38 coronary artery bypass grafting (CABG) cohort: Risk adjusted retrospective data analysis. in Presented at the AHA Scientific sessions 2010 2010: Chicago, IL.
25. Wiviott SD, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118 (16):1626-36.
26. James S, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: A substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006-16.
27. James S, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: Results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056-67.